Engineered T cell therapies (Q38623827)

4 September 2017

title

Engineered T cell therapies (English)

1 reference

4 September 2017

Anne-Christine Field

1

0 references

Waseem Qasim

object named as

Waseem Qasim

series ordinal

2

0 references

publication date

4 November 2015

1 reference

Expert Reviews in Molecular Medicine

4 September 2017

published in

1 reference

4 September 2017

volume

17

1 reference

4 September 2017

page(s)

e19

1 reference

The basic principles of chimeric antigen receptor design

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Efficient transposition of the piggyBac (PB) transposon in mammalian cells and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Tol2: a versatile gene transfer vector in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Deal watch: Pfizer and GSK join race for T cell cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Membrane-anchored peptide inhibits human immunodeficiency virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Genetically Modified Donor Leukocyte Transfusion and Graft-Versus-Leukemia Effect After Allogeneic Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene transfer to repopulating human CD34+ cells using amphotropic-, GALV-, or RD114-pseudotyped HIV-1-based vectors from stable producer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral vectors: their molecular design, safety, and use in laboratory and preclinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Targeted cell entry of lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Comparative analysis of molecular strategies attenuating positional effects in lentiviral vectors carrying multiple genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral transduction of human hematopoietic cells by HIV-1- and SIV-based vectors containing a bicistronic cassette driven by various internal promoters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene therapy clinical trials worldwide to 2012 - an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Lentiviral vectors: basic to translational

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Resistance of mature T cells to oncogene transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Stem-cell gene therapy for the Wiskott-Aldrich syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Transcription start regions in the human genome are favored targets for MLV integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Transfer of Autologous Gene-modified T Cells in HIV-infected Patients with Advanced Immunodeficiency and Drug-resistant Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Mutational analysis of the N-terminal DNA-binding domain of sleeping beauty transposase: critical residues for DNA binding and hyperactivity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydras

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Gene transfer in humans using a conditionally replicating lentiviral vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Genome editing for human gene therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Cas9 as a versatile tool for engineering biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Immune response to fetal calf serum by two adenosine deaminase-deficient patients after T cell gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Optimized lentiviral vector production and purification procedure prevents immune response after transduction of mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

A transposon and transposase system for human application

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Novel cell and gene therapies for HIV.

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Development of a self-inactivating lentivirus vector.

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

CCR5 as a natural and modulated target for inhibition of HIV.

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1017%2FERM.2015.14

7 January 2021

Identifiers

DOI

10.1017/ERM.2015.14

1 reference

4 September 2017

1 reference